Clinical Trial Update: A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) [Phase 3]

View source ↗

Summary

A Phase 3 multinational trial evaluating golidocitinib versus investigator's choice in relapsed/refractory peripheral T-cell lymphoma is currently recruiting. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Golidocitinib (golidocitinib)

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Peripheral T-cell Lymphoma | Phase 3 | Status: RECRUITING